Physician profile
Rajkumar Mariwalla
NPI 1154309037
$29,313.29
in general payments reported to CMS, 2019-2025
17 companies · $171 in 2025
The $171 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $417 · 2020: $74.74 · 2021: $20.50 · 2022: $21.06 · 2023: $35.30 · 2024: $29K · 2025: $171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $28K · Food and Beverage: $523.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $28,256.68 |
| Food and Beverage | $523.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $28,256.68 | 2024 | Gastrointestinal Videoscope, Evis Exera II Ultrasound Gastrovideoscope, Evis Exera III Colonovideoscope |
| Abbvie INC. | $489.15 | 2019-2024 | |
| Boston Scientific Corporation | $155.93 | 2025 | Axios |
| Janssen Biotech, INC. | $112.01 | 2019-2025 | Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $50.36 | 2019-2024 | Eohilia |
| Allergan, INC. | $30.47 | 2019 | |
| Intercept Pharmaceuticals, INC. | $30.16 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $29.24 | 2019-2023 | Vaxneuvance, Vaxelis, Gardasil 9 |
| Ardelyx, INC. | $22.53 | 2024 | Ibsrela |
| Redhill Biopharma INC. | $20.70 | 2020 | |
| Medtronic, INC. | $20.50 | 2021 | |
| Enterra Medical, INC. | $18.44 | 2023 | |
| Ferring Pharmaceuticals INC. | $18.44 | 2019 | |
| Pfizer INC. | $15.75 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $15.20 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $15.13 | 2024 | Voquezna |
| Kaleo, INC. | $12.60 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajkumar Mariwalla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.